scholarly journals Plant Derived Immunomodulators; A Critical Review

Author(s):  
Akey Krishna Swaroop ◽  
Chaitanya MVNL ◽  
Meena S ◽  
Gomathy Subramanian ◽  
Jawahar Natarajan ◽  
...  

The concept of immunomodulation was proposed by Edward Jenner, while working on polio vaccine in 1796. Many of the autoimmune diseases such as rheumatoid arthritis, inflammatory bowel diseases, psoriatic arthritis and system lupus erythematosus, viral diseases and, some cancers are characterized with elevated levels of "immunocytokine" gene expression, including, tumor necrosis factor-α, various interleukins, cytotoxic T-cell antigen-4, B-cell activating factor. For the treatment of these diseases, the immunologically-based therapies play the major role. In these lines, the usage of phytomedicines as immunostimulants /immunosuppressants have been enhanced considerably in last few decades and also used as a prophylactic treatment for various ailments. Phytochemicals such as flavonoids, terpenoids, polysaccharides, lactones, alkaloids, glycosides and saponins present in several plants, have been confirmed to exhibit immunomodulating properties. This review focuses on the traditional plants and their constituents which have been extensively used as immunomodulators. We have also highlighted the mechanism of action (MOA) of these plant constituents related to autophagy and adjuvanticity of drugs.

2018 ◽  
Vol 54 ◽  
pp. 329-335 ◽  
Author(s):  
Caterina Defendenti ◽  
Fabiola Atzeni ◽  
Sergio Malandrin ◽  
Sandro Ardizzone ◽  
Piero Luigi Almasio ◽  
...  

2021 ◽  
pp. 47-52
Author(s):  
T. Yu. Nuriakhmetova ◽  
I. Kh. Valeeva ◽  
Ya. O. Shevnina ◽  
N. A. Cheremina ◽  
E. V. Sukhorukova ◽  
...  

Aim. To compare the concentration and immunogenicity of TNF-α inhibitors (TNFi) and their relationship with efficacy in patients with rheumatic diseases (RD) and inflammatory bowel diseases (IBD).Materials and methods. The study included 104 patients with RD (48.1%) and IBD (51.9%) who received infliximab (INF, 30.8%), adalimumab (ADA, 38.5%) and certolizumab pegol (CZP, 30.8%). We assessed the efficacy of the drug, trough concentration of TNFi and the level of antibodies. In 30 patients, the concentration of TNFi and the level of antibodies were assessed twice with an interval of 15 [13; 17] months.Results. TNF-α inhibitors were effective in 77 (74%) patients. In the group of IBD and RD, the incidence of inefficiency was 33.3% and 18.0%, the ineffectiveness of CZP was found only in IBD group (p = 0.024). A low concentration of TNFi was detected at the first visit in 29 (53.7%) patients with IBD and 24 (48.0%) with RD, at the second visit in 4 (36.4%) patients with IBD and 9 (47.4%) with RD. In all patients with RD who did not respond to IFN and CZP, the subtherapeutic concentration was determined (p = 0.047), in the IBD group – only in 64.3% cases (p > 0.050). At the first visit, antibodies to TNFi were found in 24 (23.1%) patients, at the second visit in 7 (23.3%) exclusively in the RD group (p = 0.019), in 5 of them repeatedly. The formation of Ab was associated with 27.8% of cases of escape of the effect of TNF-α in IBD and 22.2% of cases of ineffectiveness in RD (p > 0.050).Conclusions. The incidence of TNF-α efficacy did not differ between RD and IBD, CZP ineffectiveness was observed exclusively in patients with IBD. In patients with RD, a significant relationship was found between ineffectiveness and low concentration of TNFi. The frequency of Ab formation did not differ between the groups of diseases.


2013 ◽  
Vol 4 ◽  
pp. 262-267
Author(s):  
Łukasz Durko ◽  
Olga Stasikowska-Kanicka ◽  
Małgorzata Wągrowska-Danilewicz ◽  
Marian Danilewicz ◽  
Ewa Małecka-Panas

Sign in / Sign up

Export Citation Format

Share Document